Literature DB >> 18091060

Ameloblastoma.

William M Mendenhall1, John W Werning, Rui Fernandes, Robert S Malyapa, Nancy P Mendenhall.   

Abstract

The purpose of this article is to review the pertinent literature and discuss the optimal treatment and outcomes for patients with ameloblastoma. Ameloblastoma is an uncommon benign, locally aggressive odontogenic neoplasm that usually occurs in the vicinity of the mandibular molars or ramus. Uncontrolled, ameloblastoma may cause significant morbidity and occasionally death. The median age is approximately 35 years and males and females are equally affected. The majority of ameloblastomas are multicystic, which are more difficult to eradicate than the unicystic and peripheral varieties. Although surgery is the mainstay of treatment, the extent of resection is controversial. Radical resections, including marginal and segmental mandibulectomy, result in local control rates exceeding 90%. In contrast, conservative procedures such as enucleation and/or curettage result in local control rates of approximately 80% and 50% for unicystic and multicystic ameloblastomas, respectively. Limited experience with radiotherapy indicates that it may reduce the risk of progression and result in long-term local control in the occasional patient with incompletely resectable disease. The optimal treatment for ameloblastoma is wide en bloc resection. Radiotherapy may improve the likelihood of local control in the occasional patient with incompletely resectable tumor.

Entities:  

Mesh:

Year:  2007        PMID: 18091060     DOI: 10.1097/COC.0b013e3181573e59

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  45 in total

Review 1.  Giant ameloblastoma mortality; a consequence of ignorance, poverty and fear.

Authors:  Mabel Okiemute Etetafia; Andrew Arotuah Arisi; Osawe F Omoregie
Journal:  BMJ Case Rep       Date:  2014-05-22

2.  [Maxillary ameloblastoma extending into the sinonasal tract].

Authors:  H Geddert; S Runge; U Werner; H Walendzik; A Dimmler
Journal:  Pathologe       Date:  2013-07       Impact factor: 1.011

3.  The anecdote of viral etiopathogenia in ameloblastoma and odontogenic keratocyst: Why don't we let it go?

Authors:  Bacem A E O Khalele
Journal:  J Oral Biol Craniofac Res       Date:  2017-04-14

4.  Maxillofacial tumors and tumor-like lesions in a Nigerian teaching hospital: an eleven year retrospective analysis.

Authors:  G O Bassey; O D Osunde; C E Anyanechi
Journal:  Afr Health Sci       Date:  2014-03       Impact factor: 0.927

5.  Ameloblastoma, solid/multicystic type.

Authors:  Angela M Bachmann; Ronald L Linfesty
Journal:  Head Neck Pathol       Date:  2009-10-25

6.  Unresectable Ameloblastoma Successfully Treated with Definitive Proton Therapy.

Authors:  Francesco Dionisi; Maurizio Amichetti; Carlo Algranati; Irene Giacomelli; Mattia Barbareschi; Mauro Recla; Cesare Grandi
Journal:  Int J Part Ther       Date:  2017-09-26

7.  Analysis of Prevalence and Clinical Features of Ameloblastoma and its Histopathological Subtypes in Southeast Myanmar and Lower Northern Thailand Populations: A 13-Year Retrospective Study.

Authors:  Chaidan Intapa
Journal:  J Clin Diagn Res       Date:  2017-01-01

8.  Oct-4 and CD44 in epithelial stem cells like of benign odontogenic lesions.

Authors:  Eduardo Alonso Cruz Monroy; Pedro Paulo de Andrade Santos; Maria Luiza Diniz de Sousa Lopes; Adalberto Mosqueda-Taylor; Leão Pereira Pinto; Lélia Batista de Souza
Journal:  Histochem Cell Biol       Date:  2018-07-03       Impact factor: 4.304

9.  EGFR signaling downstream of EGF regulates migration, invasion, and MMP secretion of immortalized cells derived from human ameloblastoma.

Authors:  Marina Rolo Pinheiro da Rosa; Aline Semblano Carreira Falcão; Hellen Thais Fuzii; Maria Sueli da Silva Kataoka; André L R Ribeiro; Enrique Boccardo; Adriane Sousa de Siqueira; Ruy G Jaeger; João de Jesus Viana Pinheiro; Sérgio de Melo Alves Júnior
Journal:  Tumour Biol       Date:  2014-08-07

10.  Expression of RECK and matrix metalloproteinase-2 in ameloblastoma.

Authors:  Bin Zhang; Jin Zhang; Zhi-Ying Xu; Hong-Liang Xie
Journal:  BMC Cancer       Date:  2009-12-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.